Synergy Asset Management LLC Buys 4,924 Shares of Gilead Sciences, Inc. $GILD

Synergy Asset Management LLC grew its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 100.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,848 shares of the biopharmaceutical company’s stock after acquiring an additional 4,924 shares during the quarter. Synergy Asset Management LLC’s holdings in Gilead Sciences were worth $1,211,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in GILD. GoalVest Advisory LLC boosted its holdings in Gilead Sciences by 7,566.7% during the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 227 shares during the last quarter. Harbor Asset Planning Inc. purchased a new stake in Gilead Sciences in the 2nd quarter valued at about $27,000. Howard Hughes Medical Institute bought a new position in shares of Gilead Sciences during the 2nd quarter worth approximately $30,000. Putney Financial Group LLC boosted its stake in shares of Gilead Sciences by 53.4% in the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 94 shares during the last quarter. Finally, Kilter Group LLC bought a new position in shares of Gilead Sciences in the second quarter valued at approximately $33,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Down 0.9%

Shares of GILD opened at $121.60 on Friday. The business has a 50-day moving average of $123.05 and a 200 day moving average of $117.11. Gilead Sciences, Inc. has a fifty-two week low of $88.57 and a fifty-two week high of $128.70. The firm has a market cap of $150.87 billion, a P/E ratio of 18.85, a price-to-earnings-growth ratio of 0.65 and a beta of 0.33. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, beating the consensus estimate of $2.16 by $0.31. The business had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The company’s revenue was up 3.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, December 30th. Investors of record on Monday, December 15th were paid a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date was Monday, December 15th. Gilead Sciences’s dividend payout ratio is presently 48.99%.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. BMO Capital Markets set a $135.00 price objective on Gilead Sciences in a research note on Tuesday, November 25th. Citigroup lifted their target price on Gilead Sciences from $125.00 to $135.00 and gave the stock a “buy” rating in a research note on Wednesday, October 8th. Sanford C. Bernstein set a $135.00 price target on shares of Gilead Sciences and gave the company an “outperform” rating in a research report on Monday, December 29th. Morgan Stanley raised their price objective on shares of Gilead Sciences from $147.00 to $151.00 and gave the stock an “overweight” rating in a report on Friday, December 12th. Finally, Royal Bank Of Canada lifted their price objective on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock a “sector perform” rating in a research report on Friday, October 31st. Two analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $131.68.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $122.00, for a total value of $366,000.00. Following the completion of the transaction, the chief financial officer directly owned 153,503 shares in the company, valued at approximately $18,727,366. The trade was a 1.92% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction on Friday, November 28th. The stock was sold at an average price of $125.08, for a total value of $625,400.00. Following the sale, the director owned 8,920 shares in the company, valued at approximately $1,115,713.60. This represents a 35.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 136,257 shares of company stock worth $16,855,192 in the last 90 days. 0.27% of the stock is currently owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.